Xian Qiu
Xian Qiu
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Search for other papers by Xian Qiu in
Google Scholar
PubMed
Search for other papers by Xian Qiu in
Google Scholar
PubMed
Lin Cheng
Lin Cheng
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Ri Sa
Ri Sa
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China
Search for other papers by Ri Sa in
Google Scholar
PubMed
Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, China
Search for other papers by Ri Sa in
Google Scholar
PubMed
Hao Fu
Hao Fu
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Hao Fu in
Google Scholar
PubMed
Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen, China
Search for other papers by Hao Fu in
Google Scholar
PubMed
Yuchen Jin
Yuchen Jin
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Libo Chen
Libo Chen
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China
Search for other papers by Libo Chen in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
in the phase 3 clinical trial of cabozantinib as salvage therapy for patients with first-line TKI resistance ( 9 ). Nevertheless, real-world data on salvage therapy of RR-DTC resistant to first-line TKIs remain unavailable. Apatinib, an orally
